Close Menu

NEW YORK (GenomeWeb) – The GenomeWeb Index fell nearly 3 percent in April, posting its first loss for 2019 amid wider losses for biotech stocks.

The index underperformed the Dow Jones Industrial Average and the Nasdaq, which gained nearly 3 percent and nearly 5 percent, respectively, but outperformed the Nasdaq Biotechnology Index, which fell nearly 5 percent. Individual stock performance in the April GenomeWeb Index was mostly negative as 17 of the 30 stocks saw losses and 13 saw gains.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.